Skip to content
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each stock might be going. […]...
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of March 31st, a week after the market trough. Now, we are […]...
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend many resources and use tools that are not […]...
* Insider buying can be an encouraging signal for potential investors. * Insiders at biotechs took advantage of initial and secondary public offerings. * Notable insider purchases were also seen at some industrial companies.Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit. So insider buying can be an encouraging signal for potential investors, particularly during periods of uncertainty.Insiders continued to add shares despite overall market volatility and economic uncertainty. Here are some of the most noteworthy insider purchases reported in the past week.Nkarta, Inc. (NASDAQ: NKTX) saw a number of beneficial owners buy into the initial public offering, including GlaxoSmithKline plc (NYSE: GSK). Altogether, they picked up more than 9.83 million shares of this biopharmaceutical company for $18 each. That totaled nearly $187 million.Two Akero Therapeutics Inc (NASDAQ: AKRO)...
* This weekend's Barron's cover story presents the publication's latest annual ranking of the best annuities. * Other featured articles look at dividend aristocrats roaring back, the political considerations for vaccine makers and retail stocks bucking the trend. * Also: the prospects for index providers, an internet holding company a big bank and more.Cover story "The Best Annuities" by Karen Hube presents a look at the best of what the industry has to offer. For its latest annual ranking, Barron's compiled 100 of the best annuities based on assumptions such as age, gender, size of investment and time horizon.Darren Fonda's "Why MSCI and S&P Global Are Worth Buying at Any Price" points out that investors have rewarded the index providers' growth and could lift MSCI Inc (NYSE: MSCI) and S&P Global Inc (NYSE: SPGI) stocks further as profits climb.In "Dollar Stores Are a Retail Growth Story Even in a Downturn," Teresa...
The typical mortgage holder is missing out on an opportunity save thousands....
